We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 5,469

Sanofi seeks IPR of Cabilly patent
  • Foley & Lardner LLP
  • USA
  • July 30 2015

On July 27, 2015, Sanofi-aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. filed a petition for Inter Partes Review (IPR) of the “Cabilly II”


Watch out for a wide omnibus (claim)
  • Minter Ellison
  • Australia
  • July 30 2015

Old-style 'omnibus claims' are often overlooked in patent infringement disputes. The usual assumption is that these claims are very narrow in scope


Obviousness inquiry for ocular patents not mis-framed
  • McDermott Will & Emery
  • USA
  • July 30 2015

Affirming the finding by the U.S. District Court for the District of New Jersey that defendant failed to prove Plaintiffs’ patents directed to


Federal Circuit relaxes limits of safe harbor for post-approval studies
  • McDermott Will & Emery
  • USA
  • July 30 2015

Affirming the U.S. District Court for the District of Maryland, the U.S. Court of Appeals for the Federal Circuit recently held the “safe harbor”


Reverse payment settlements subject to antitrust challenge
  • McDermott Will & Emery
  • USA
  • July 30 2015

In a class action case assessing the implications of antitrust law in a patent infringement and validity settlement agreement, the Supreme Court of


Supreme Court holds good faith belief of patent invalidity is not a defense to induced infringement
  • McDermott Will & Emery
  • USA
  • July 30 2015

Pharmaceutical patents commonly include claims directed to methods of treatment using a purportedly novel compound, formulation or treatment regimen


Generic labels can omit orphan drug indications to avoid brand exclusivity rights
  • McDermott Will & Emery
  • USA
  • July 30 2015

Two hours after the U.S. Food and Drug Administration (FDA) approved generic versions of Abilify (aripiprazole) (excluding pediatric indications and


Federal court affirms invalidity of sterile budesonide claims
  • McDermott Will & Emery
  • USA
  • July 30 2015

The U.S. Court of Appeals for the Federal Circuit recently affirmed the obviousness of claims directed to sterile, pharmaceutically effective


Branded company’s patent infringement suit ‘KO’d’ by judgment on the pleadings based on the disclosure-dedication rule
  • McDermott Will & Emery
  • USA
  • July 30 2015

Not often is a patent infringement lawsuit filed pursuant to the Hatch-Waxman Act dismissed as a result of a judgment on the pleadings. However


Suspected off-label infringing uses do not equal inducement
  • McDermott Will & Emery
  • USA
  • July 30 2015

On May 6, 2015, the U.S. Court of Appeals for the Federal Circuit issued its full opinion affirming the U.S. District Court for the District of